Safety and efficacy of intramuscular human placenta‐derived mesenchymal stromal‐like cells (cenplacel [PDA‐002]) in patients who have a diabetic foot ulcer with peripheral arterial disease1. Issue 5 (30th January 2017)

• Record Type: Journal Article
• Authors: Wu, Stephanie C; Pollak, Richard; Frykberg, Robert G; Zhou, Wei; Karnoub, Maha; Jankovic, Vladimir; Fischkoff, Steven A; Chitkara, Denesh
• Is Part Of: International wound journal. Volume 14:Issue 5(2017)
• Page Start: 823
• Page End: 829
• Publication Date: 2017-01-30
• Subjects: Cenplacel -- Diabetic foot ulcer -- Mesenchymal‐like cells -- Peripheral arterial disease -- Placenta‐derived cell population; Wounds and injuries -- Treatment -- Periodicals; Wounds and injuries -- Periodicals; Wound healing -- Periodicals; 617.1005
• DOI: 10.1111/iwj.12715
• Languages: English
• ISSNs: 1742-4801

Abstract

Abstract: The objective of this study was to examine the safety of cenplacel (PDA‐002) in patients with peripheral arterial disease (PAD) and a diabetic foot ulcer (DFU). Cenplacel is a mesenchymal‐like cell population derived from full‐term human placenta. This phase 1, dose‐escalation study investigated cenplacel in diabetic patients with chronic DFUs (Wagner grade 1 or grade 2) and PAD [ankle‐brachial index (ABI) >0·5 and ≤0·9], enrolled sequentially into each of four dose cohorts (3 × 10 6, 10 × 10 6, 30 × 10 6 and 100 × 10 6 cells; administered intramuscularly on study days 1 and 8 in combination with standard of care). Overall, cenplacel was well tolerated in all 15 patients in the study. Before enrollment, nine patients had an ulcer for ≥6 months and 11 had an ABI of 0·7–0·85. No patient met dose‐limiting toxicity criteria and no treatment‐related serious adverse events were reported. There was preliminary evidence of ulcer healing in seven patients (five complete; two partial) within 3 months of cenplacel treatment, and circulating endothelial cell levels (a biomarker of vascular injury in PAD) were decreased within 1 month. Cenplacel was generally safe and well tolerated in patients with chronic DFUs and PAD. Outcomes from this study informed the doses, endpoints, biomarkers and patient population for an ongoing phase 2 trial.